Alektiar K M, Hu K, Anderson L, Brennan M F, Harrison L B
Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Int J Radiat Oncol Biol Phys. 2000 Apr 1;47(1):157-63. doi: 10.1016/s0360-3016(99)00546-5.
Retroperitoneal sarcomas represent a formidable challenge to the treating oncologist due to their location, large size, and poor prognosis. The purpose of this study was to determine if the addition of high-dose-rate intraoperative radiation therapy (HDR-IORT) to surgery and external beam radiotherapy (EBRT) would improve the outcome in these patients.
Thirty-two patients with retroperitoneal soft tissue sarcoma were prospectively treated according to a protocol that included maximal tumor resection, HDR-IORT, and postoperative EBRT when feasible. Twelve patients presented with primary and 20 with locally recurrent disease. The tumors were high-grade in 20 patients and low-grade in 12 patients. Complete gross resection was achieved in 30 patients. HDR-IORT was given to a dose of 12-15 Gy. Additional EBRT was given to 78% of patients to a dose of 45-50.4 Gy. The two patients with gross residual disease received an additional I-125 permanent implant to a median peripheral dose of 140-160 Gy. The median follow-up was 33 months (range 1-77 mo).
The 5-year actuarial local control rate for the whole group was 62%. For patients with primary disease, the local control rate was 74% compared to 54% in patients with recurrent disease (p = 0.4). The overall 5-year distant metastasis-free survival rate was 82%. In patients with high-grade tumors the rate was 70% vs. 100% in those with low-grade tumors. This difference was statistically significant, p = 0.05. The 5-year disease-free and overall survival rates were 55% and 45%, respectively. The most common type of post-treatment complication was gastrointestinal obstruction (18%) followed by fistula formation (9%), peripheral neuropathy (6%), hydronephrosis (3%), and wound complication (3%).
We are encouraged by the favorable local control rate and the acceptable morbidity with this new technique applied to a challenging patient population.
腹膜后肉瘤因其位置、体积大及预后差,给肿瘤治疗医生带来了巨大挑战。本研究的目的是确定在手术和外照射放疗(EBRT)基础上增加高剂量率术中放疗(HDR-IORT)是否能改善这些患者的治疗结果。
32例腹膜后软组织肉瘤患者按照一项方案进行前瞻性治疗,该方案包括尽可能进行最大程度的肿瘤切除、HDR-IORT,以及在可行时进行术后EBRT。12例为原发性疾病,20例为局部复发性疾病。20例患者的肿瘤为高级别肿瘤,12例为低级别肿瘤。30例患者实现了肿瘤大体完全切除。HDR-IORT的剂量为12 - 15 Gy。78%的患者接受了额外的EBRT,剂量为45 - 50.4 Gy。两名有大体残留病灶的患者接受了额外的I - 125永久性植入,外周中位剂量为140 - 160 Gy。中位随访时间为33个月(范围1 - 77个月)。
全组5年精算局部控制率为62%。原发性疾病患者的局部控制率为74%,而复发性疾病患者为54%(p = 0.4)。5年总体无远处转移生存率为82%。高级别肿瘤患者的这一比率为70%,而低级别肿瘤患者为100%。这一差异具有统计学意义,p = 0.05。5年无病生存率和总生存率分别为55%和45%。最常见的治疗后并发症类型是胃肠道梗阻(18%),其次是瘘管形成(9%)、周围神经病变(6%)、肾积水(3%)和伤口并发症(3%)。
将这项新技术应用于具有挑战性的患者群体,其良好的局部控制率和可接受的发病率让我们备受鼓舞。